Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Imfinzi under the microscope: how does it perform outside the lab?

NCT ID NCT04068168

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracked over 700 people in Korea who were already receiving the cancer drug Imfinzi (durvalumab) for lung or biliary tract cancer. The goal was to see how safe and effective the drug is in everyday medical practice, not just in strict clinical trials. Researchers monitored side effects and how long the drug kept the cancer from growing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

712 people

The number who actually took part.

Started

Jan 2020

Finished

Dec 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Imfinzi treatment according to the approved label

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible for Imfinzi treatment according to the approved label * Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: * Current participation in any interventional trial * Other off-label indications according to the approved label

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biliary tract cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

biliary tract cancer Biliary Tract Neoplasms lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer, biliary tract cancer

Contacts and locations

Locations

  • Research Site

    Anyang-si, South Korea, South Korea

  • Research Site

    Bucheon-si, South Korea, South Korea

  • Research Site

    Busan, South Korea, South Korea

  • Research Site

    Changwon, South Korea, South Korea

  • Research Site

    Changwon-si, South Korea, South Korea

  • Research Site

    Cheonan, South Korea, South Korea

  • Research Site

    Chuncheon, South Korea, South Korea

  • Research Site

    Daegu, South Korea, South Korea

  • Research Site

    Daejeon, South Korea, South Korea

  • Research Site

    Goyang-si, South Korea, South Korea

  • Research Site

    Gwangju, South Korea, South Korea

  • Research Site

    Hwasun-gun, South Korea, South Korea

  • Research Site

    Iksan-si, South Korea, South Korea

  • Research Site

    Incheon, South Korea, South Korea

  • Research Site

    Jeju-do, South Korea, South Korea

  • Research Site

    Jeonju, South Korea, South Korea

  • Research Site

    Pohang-si, South Korea, South Korea

  • Research Site

    Seongnam-si, South Korea, South Korea

  • Research Site

    Seoul, South Korea, South Korea

  • Research Site

    Suwon, South Korea, South Korea

  • Research Site

    Uijeongbu-si, South Korea, South Korea

  • Research Site

    Wŏnju, South Korea, South Korea

  • Research Site

    Yangsan, South Korea, South Korea

  • Research Site

    Yongin-si, South Korea, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.